home / stock / vtyx / vtyx message board
Subject | By | Source | When |
---|---|---|---|
just the news we needed | DewDiligence | investorshub | 07/02/2023 2:16:23 AM |
Price now up | crudeoil24 | investorshub | 06/13/2023 7:26:13 PM |
just the news we needed | crudeoil24 | investorshub | 06/12/2023 8:45:23 AM |
Ventyx Biosciences, Inc. (Nasdaq: $VTYX) (Ventyx), a clinical-stage | crudeoil24 | investorshub | 09/19/2022 4:15:16 PM |
znewcar1: VTYX 64% v15,6M c38.11 f50,9M H41.29 ML16.91 off the 20dma@19.73 | znewcar1 | investorshangout | 09/13/2022 1:57:39 AM |
$VTYX IS A GREAT $$$$$ OPPORTUNITY. | crudeoil24 | investorshub | 09/12/2022 6:37:24 PM |
Complex, but GOOD!!! | Invest-in-America | investorshub | 09/12/2022 6:21:00 PM |
Ventyx Shares Surge 59% After Bristol Myers Drug | crudeoil24 | investorshub | 09/12/2022 6:19:20 PM |
THANKS!! | Invest-in-America | investorshub | 09/12/2022 6:06:18 PM |
Today's pop is due to $BMY's FDA approval | DewDiligence | investorshub | 09/12/2022 6:04:12 PM |
$VTYX: Soaring today??? | Invest-in-America | investorshub | 09/12/2022 2:39:50 PM |
znewcar1: VTYX 31% v2,1M c24.55 f50,8M H27.65 ML12.87 | znewcar1 | investorshangout | 08/16/2022 8:32:06 PM |
VTYX reports phase-1 data for VTX858, a potential | DewDiligence | investorshub | 08/15/2022 9:41:23 PM |
$VTYX: $125Mlly IPO coming........... | makinezmoney | investorshub | 10/18/2021 6:44:14 PM |
News, Short Squeeze, Breakout and More Instantly...
Ventyx Biosciences Inc. Company Name:
VTYX Stock Symbol:
NASDAQ Market:
Phase 2a trials of CNS-Penetrant NLRP3 Inhibitor VTX3232 to initiate in H2 2024 in patients with early Parkinson’s disease and in participants with obesity with certain additional cardiovascular risk factors Cash, cash equivalents and marketable securities of $302.6 million as ...
SAN DIEGO, May 02, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (NASDAQ:VTYX), ("Ventyx"), a clinical-stage biopharmaceutical company focus...
SAN DIEGO, May 02, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX), (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory diseases with significant unmet medical need, today announced th...